TriVascular is a technology company.
TriVascular has raised $255.0M across 5 funding rounds.
TriVascular has raised $255.0M in total across 5 funding rounds.
TriVascular has raised $255.0M in total across 5 funding rounds.
TriVascular's investors include MPM Capital, Pivotal bioVenture Partners, Sofinnova Investments, SR One Capital Management.
TriVascular Technologies is a medical device company that develops innovative endovascular grafts for aortic repair, specifically targeting abdominal aortic aneurysms (AAA) through minimally invasive endovascular aortic repair (EVAR) procedures.[1][2] Founded in 1998 and headquartered in Santa Rosa, California, it pioneered design and manufacturing technologies to address unmet clinical needs, expanding EVAR candidacy with products like novel grafts and later CustomSeal technology.[1][2][4] The company served physicians and patients requiring AAA treatment, solving challenges in traditional surgery by offering safer, more effective endovascular solutions; it raised $220.67M before being acquired by Endologix in February 2016.[2]
TriVascular was founded in 1998 in Santa Rosa, California, focusing from the outset on advancing EVAR technologies for aortic aneurysms.[1][2] Key early developments included partnerships with leading clinicians worldwide to create novel endovascular grafts that improved upon existing options.[1] Pivotal moments included FDA approvals for products and the introduction of next-generation CustomSeal technology, a biocompatible fill polymer, culminating in its acquisition by Endologix in 2016, which integrated its innovations into a larger vascular disease treatment portfolio.[2][3][4]
TriVascular rode the wave of minimally invasive vascular interventions, capitalizing on the growing demand for EVAR amid rising AAA prevalence and preferences for less traumatic procedures over open surgery.[1][2] Its timing aligned with medtech shifts toward advanced stent grafts and polymers, influencing ecosystem growth by setting benchmarks for aneurysm treatment efficacy and physician training via tools like animations.[3] Market forces like aging populations and procedural adoption favored its grafts, which expanded addressable markets and spurred competitors in aortic repair devices.[2]
Post-2016 acquisition, TriVascular's technologies live on within Endologix, driving ongoing EVAR advancements amid trends like AI-enhanced imaging and bioresorbable materials.[2] Expect evolution toward broader aortic disorders and procedural simulations, amplifying influence in vascular medtech as minimally invasive standards solidify.[3] This legacy underscores how targeted innovation can transform aneurysm care, tying back to its foundational commitment to optimal endovascular solutions.[1]
TriVascular has raised $255.0M across 5 funding rounds. Most recently, it raised $40.0M Series E in November 2013.